GlassScriptPhysician profile
Anne Boudreaux
NPI 1972568277
$934.14
in general payments reported to CMS, 2019-2025
25 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.82 · 2020: $37.66 · 2021: $172 · 2022: $78.96 · 2023: $124 · 2024: $275 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $596.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $225.56 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $103.30 | 2024 | |
| Abbott Laboratories | $71.51 | 2022-2025 | Freestyle Libre |
| Amgen INC. | $59.75 | 2019-2021 | |
| Abbvie INC. | $49.98 | 2021-2023 | Vraylar |
| Adlon Therapeutics L.P. | $39.42 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.90 | 2021 | |
| Supernus Pharmaceuticals, INC. | $29.66 | 2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $27.93 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $27.77 | 2021-2023 | Steglatro, Belsomra |
| Dexcom, INC. | $24.52 | 2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $22.17 | 2024 | |
| Cranial Technologies, INC | $20.53 | 2024 | Doc Band |
| Atricure, INC. | $20.28 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.51 | 2025 | Xifaxan |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $19.43 | 2025 | Zenpep |
| Seqirus USA INC | $18.59 | 2020 | |
| Cipher Pharmaceuticals US LLC | $18.28 | 2025 | Spinosad, Natroba |
| Eisai INC. | $17.63 | 2021 | |
| Tris Pharma INC | $17.02 | 2022 | |
| Sumitomo Pharma America, INC. | $16.55 | 2025 | Gemtesa |
| Collegium Pharmaceutical, INC. | $15.70 | 2025 | Jornay Pm |
| Novo Nordisk INC | $14.57 | 2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.69 | 2019 | |
| Shire North American Group INC | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Boudreaux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.